NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

Compare

795.35

+7.16

(+0.91%)

At close: 1:00 p.m. EST

795.45

+0.10

(+0.01%)

After hours: 4:27 p.m. EST

Galderma Bets on Skin Drug to Turn Around Pharma Business

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations.

The Wall Street Journal 4 hours ago

LLY
+0.91%
ABBV
-0.08%
REGN
Why Is Lilly (LLY) Down 5% Since Last Earnings Report?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 4 hours ago

LLY
+0.91%
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks 7 hours ago

LLY
+0.91%
Radiopharmaceutical trials face extra complexities due to nuclear red tape

From additional regulatory requirements to transport refusal, the field of radiopharmaceutical trials can face additional red tape.

Clinical Trials Arena 9 hours ago

GLDAF

LLY
+0.91%
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer

Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.

Zacks yesterday

NVS
+0.86%
PFE
+1.47%
LLY
+0.91%
Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion. Why is Eli Lilly stock struggling of late? Eli Lilly has been a fantastic growth stock to own in recent years.

Motley Fool yesterday

LLY
+0.91%
MHRA approves Eli Lilly’s Alzheimer’s diagnostic imaging agent Tauvid

Tauvid is to be used in PET scans to identify tau buildup to better diagnose Alzheimer’s disease.

Medical Device Network 2 days ago

LLY
+0.91%
The race for approval: oral GLP-1R therapies in obesity

With expected sales estimated to exceed $126 billion by 2030, this drug category presents a lucrative market.

Pharmaceutical Technology 2 days ago

NVO
+0.63%
LLY
+0.91%
LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs

The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the drugs and make them affordable.

Zacks 2 days ago

NVO
+0.63%
LLY
+0.91%
The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue growth thanks to the fact that patients need their medicines -- so will continue with them no matter what the economy is doing. A top pharma stock also may have one particular star product that brings in blockbuster revenue, and this growth could drive stock performance.

Motley Fool 2 days ago

LLY
+0.91%
Why Amgen's Weight Loss Result Is a Win for Eli Lilly

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks. On the surface, 20% weight loss after 52 weeks for a monthly injection is commendable.

Motley Fool 2 days ago

AMGN
+1.00%
LLY
+0.91%
Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.

Investor's Business Daily 2 days ago

LLY
+0.91%
AMGN
+1.00%
VKTX
White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the proposal.

The Wall Street Journal 3 days ago

LLY
+0.91%
PFE
+1.47%
Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?

Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a buy?

Investor's Business Daily 3 days ago

LLY
+0.91%
NVO
+0.63%
BIIB
Novo Nordisk Says White House Obesity Plan Is Step in Right Direction

Novo Nordisk CFO Karsten Knudsen said in an interview that the company is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that it is too early to say how the plans might be affected by the incoming Trump administration.

The Wall Street Journal 3 days ago

LLY
+0.91%
Eli Lilly Stock Climbs 5% as White House Backs Medicare Obesity Drug Proposal

Obesity Drugs Like Ozempic and Wegovy May Soon Be Covered by Medicare, Sparking Stock Gains

GuruFocus.com 3 days ago

LLY
+0.91%
Medicare Could Pay for Wegovy. Don’t Count On It.

The Biden administration said it would allow the program to pay for GLP-1 anti-obesity drugs, but the Trump administration would have to allow that to happen.

Barrons.com 3 days ago

LLY
+0.91%
NVO
+0.63%
Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.

The pharmaceutical company's MariTide treatment performed well in a Phase 2 study but not as well as Wall Street expected.

Barrons.com 3 days ago

AMGN
+1.00%
LLY
+0.91%
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs

Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans including Medicare and Medicaid.

Investopedia 3 days ago

LLY
+0.91%
NVO
+0.63%
Biden Proposal to Cover Obesity Drugs Sets Up Quandary for Trump

(Bloomberg) -- The Biden administration is proposing a rule that would require the US government to cover obesity drugs for millions of Americans, teeing up a financial and political challenge for President-elect Donald Trump as he prepares to take office.Most Read from BloombergNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Italy’s Motor City, Car-Free Options Are GrowingIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldNYC's Underground Steam Syste

Bloomberg 3 days ago

LLY
+0.91%
NVO
+0.63%

Performance Overview

Return	LLY	S&P 500
YTD	+37.33%	+26.47%
1-Year	+35.32%	+32.44%
3-Year	+214.74%	+31.29%

News

Life

Movies

Finance

Sports

Yahoo Finance

Eli Lilly and Company (LLY)

Galderma Bets on Skin Drug to Turn Around Pharma Business

Why Is Lilly (LLY) Down 5% Since Last Earnings Report?

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Radiopharmaceutical trials face extra complexities due to nuclear red tape

EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer

Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?

MHRA approves Eli Lilly’s Alzheimer’s diagnostic imaging agent Tauvid

The race for approval: oral GLP-1R therapies in obesity

LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs

The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now

Why Amgen's Weight Loss Result Is a Win for Eli Lilly

Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment

White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs

Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?

Novo Nordisk Says White House Obesity Plan Is Step in Right Direction

Eli Lilly Stock Climbs 5% as White House Backs Medicare Obesity Drug Proposal

Medicare Could Pay for Wegovy. Don’t Count On It.

Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.

Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs

Biden Proposal to Cover Obesity Drugs Sets Up Quandary for Trump

Performance Overview